Nerve growth factor gene therapy in Alzheimer disease
- PMID: 17545746
- DOI: 10.1097/WAD.0b013e318068d6d2
Nerve growth factor gene therapy in Alzheimer disease
Abstract
Nervous system growth factors potently stimulate cell function and prevent neuronal death. These broad effects on survival and function arise from direct downstream activation of antiapoptotic pathways, inhibition of proapoptotic pathways, and stimulation of functionally important cellular mechanisms including ERK/MAP kinase and CREB. Thus, as a class, growth factors offer the potential to treat neurodegenerative disorders for the first time by preventing neuronal degeneration rather than compensating for cell loss after it has occurred. Different growth factors affect distinct and specific populations of neurons: the first nervous system growth factor identified, nerve growth factor, potentially stimulates the survival and function of basal forebrain cholinergic neurons, suggesting that nerve growth factor could be a means for reducing the cholinergic component of cell degeneration in Alzheimer disease. This review will discuss the transition of growth factors from preclinical studies to human clinical trials in Alzheimer disease. The implementation of clinical testing of growth factor therapy for neurologic disease has been constrained by the dual need to achieve adequate concentrations of these proteins in specific brain regions containing degenerating neurons, and preventing growth factor spread to non_targeted regions to avoid adverse effects. Gene therapy is one of a limited number of potential methods for achieving these requirements.
Similar articles
-
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease.Nat Med. 2005 May;11(5):551-5. doi: 10.1038/nm1239. Epub 2005 Apr 24. Nat Med. 2005. PMID: 15852017 Clinical Trial.
-
Nerve growth factor gene delivery: animal models to clinical trials.Dev Neurobiol. 2007 Aug;67(9):1204-15. doi: 10.1002/dneu.20510. Dev Neurobiol. 2007. PMID: 17514712 Review.
-
A new tool in the battle against Alzheimer's disease and aging: ex vivo gene therapy.Rejuvenation Res. 2005 Fall;8(3):131-4. doi: 10.1089/rej.2005.8.131. Rejuvenation Res. 2005. PMID: 16144466 Review.
-
[Nerve growth factor: possibilities and limitations of its clinical application].Rev Neurol. 1999 Sep 1-15;29(5):439-47. Rev Neurol. 1999. PMID: 10584248 Review. Spanish.
-
[Nerve growth factor in neurodegeneration and neurorestorative therapy].Rev Neurol. 2004 May 16-31;38(10):957-71. Rev Neurol. 2004. PMID: 15175980 Review. Spanish.
Cited by
-
Increased expression of the homologue of enhancer-of-split 1 protects neurons from beta amyloid neurotoxicity and hints at an alternative role for transforming growth factor beta1 as a neuroprotector.Alzheimers Res Ther. 2012 Jul 31;4(4):31. doi: 10.1186/alzrt134. Alzheimers Res Ther. 2012. PMID: 22849569 Free PMC article.
-
Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic.CNS Drugs. 2013 Jul;27(7):493-503. doi: 10.1007/s40263-013-0068-8. CNS Drugs. 2013. PMID: 23681979 Review.
-
Ciliary neurotrophic factor cell-based delivery prevents synaptic impairment and improves memory in mouse models of Alzheimer's disease.J Neurosci. 2010 Jun 2;30(22):7516-27. doi: 10.1523/JNEUROSCI.4182-09.2010. J Neurosci. 2010. PMID: 20519526 Free PMC article.
-
Alzheimer disease.Dis Mon. 2010 Sep;56(9):484-546. doi: 10.1016/j.disamonth.2010.06.001. Dis Mon. 2010. PMID: 20831921 Free PMC article. Review. No abstract available.
-
From molecular to nanotechnology strategies for delivery of neurotrophins: emphasis on brain-derived neurotrophic factor (BDNF).Pharmaceutics. 2013 Feb 8;5(1):127-67. doi: 10.3390/pharmaceutics5010127. Pharmaceutics. 2013. PMID: 24300402 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
